Literature DB >> 16684800

Emtricitabine intolerance in treatment-experienced patients switched from lamivudine: a method of assessing toxicity.

Katrina Pollock, Justin Stebbing, Mark Bower, Brian Gazzard, Mark Nelson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16684800     DOI: 10.1093/jac/dkl179

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  5 in total

1.  HIV-associated Neurocognitive Disorders and Antiretroviral Therapy: Current Concepts and Controversies.

Authors:  Mark R Etherton; Jennifer L Lyons; Kevin L Ard
Journal:  Curr Infect Dis Rep       Date:  2015-06       Impact factor: 3.725

Review 2.  Neuropsychiatric Effects of HIV Antiviral Medications.

Authors:  Glenn J Treisman; Olivia Soudry
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

Review 3.  Neurological and psychiatric adverse effects of antiretroviral drugs.

Authors:  Michael S Abers; Wayne X Shandera; Joseph S Kass
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

4.  Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.

Authors:  R Palacios; C Hidalgo; M J Ríos; A Rivero; L Muñoz; F Lozano; V Gutiérrez-Ravé; M C Gálvez; A del Arco; J Santos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-10-08       Impact factor: 3.267

5.  Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs.

Authors:  Francesc Homar; Virginia Lozano; Juan Martínez-Gómez; Itziar Oyagüez; Antonio Pareja; Antoni Payeras; Joaquín Serrano; Carmen Carratalá; Miguel Angel Casado
Journal:  Health Econ Rev       Date:  2012-09-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.